Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study.

Downing A, Wright P, Hounsome L, Selby P, Wilding S, Watson E, Wagland R, Kind P, Donnelly DW, Butcher H, Catto JWF, Cross W, Mason M, Sharp L, Weller D, Velikova G, McCaughan E, Mottram R, Allen M, Kearney T, McSorley O, Huws DW, Brewster DH, McNair E, Gavin A, Glaser AW.

Lancet Oncol. 2019 Mar;20(3):436-447. doi: 10.1016/S1470-2045(18)30780-0. Epub 2019 Jan 31.

PMID:
30713036
2.

Urinary, bowel and sexual health in older men from Northern Ireland.

Donnelly DW, Donnelly C, Kearney T, Weller D, Sharp L, Downing A, Wilding S, Wright P, Kind P, Catto JWF, Cross WR, Mason MD, McCaughan E, Wagland R, Watson E, Mottram R, Allen M, Butcher H, Hounsome L, Selby P, Huws D, Brewster DH, McNair E, Rivas C, Nayoan J, Horton M, Matheson L, Glaser AW, Gavin A.

BJU Int. 2018 Nov;122(5):845-857. doi: 10.1111/bju.14182. Epub 2018 Mar 25.

3.

Symptoms, unmet needs, psychological well-being and health status in survivors of prostate cancer: implications for redesigning follow-up.

Watson E, Shinkins B, Frith E, Neal D, Hamdy F, Walter F, Weller D, Wilkinson C, Faithfull S, Wolstenholme J, Sooriakumaran P, Kastner C, Campbell C, Neal R, Butcher H, Matthews M, Perera R, Rose P.

BJU Int. 2016 Jun;117(6B):E10-9. doi: 10.1111/bju.13122. Epub 2015 May 23.

4.

Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.

Ahmed HU, Hindley RG, Dickinson L, Freeman A, Kirkham AP, Sahu M, Scott R, Allen C, Van der Meulen J, Emberton M.

Lancet Oncol. 2012 Jun;13(6):622-32. doi: 10.1016/S1470-2045(12)70121-3. Epub 2012 Apr 17.

5.

Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life.

Lane A, Metcalfe C, Young GJ, Peters TJ, Blazeby J, Avery KN, Dedman D, Down L, Mason MD, Neal DE, Hamdy FC, Donovan JL; ProtecT Study group.

BJU Int. 2016 Dec;118(6):869-879. doi: 10.1111/bju.13582. Epub 2016 Aug 17.

6.

Racial and Ethnic Variation in Health-Related Quality of Life Scores Prior to Prostate Cancer Treatment.

Reading SR, Porter KR, Slezak JM, Harrison TN, Gelfond JS, Chien GW, Jacobsen SJ.

Sex Med. 2017 Dec;5(4):e219-e228. doi: 10.1016/j.esxm.2017.07.002. Epub 2017 Aug 18.

7.
8.

Health-related quality of life measured using the EQ-5D-5L: South Australian population norms.

McCaffrey N, Kaambwa B, Currow DC, Ratcliffe J.

Health Qual Life Outcomes. 2016 Sep 20;14(1):133. doi: 10.1186/s12955-016-0537-0.

9.

A prospective study of health-related quality-of-life outcomes for patients with low-risk prostate cancer managed by active surveillance or radiation therapy.

Banerji JS, Hurwitz LM, Cullen J, Wolff EM, Levie KE, Rosner IL, Brand TC, LʼEsperance JO, Sterbis JR, Porter CR.

Urol Oncol. 2017 May;35(5):234-242. doi: 10.1016/j.urolonc.2016.12.015. Epub 2017 Jan 19.

PMID:
28110975
10.

Long-term quality of life in disadvantaged men with prostate cancer on androgen-deprivation therapy.

Sevilla C, Maliski SL, Kwan L, Connor SE, Litwin MS.

Prostate Cancer Prostatic Dis. 2012 Sep;15(3):237-43. doi: 10.1038/pcan.2011.71. Epub 2012 Jan 31.

PMID:
22289781
11.

Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.

Chi KN, Protheroe A, Rodríguez-Antolín A, Facchini G, Suttman H, Matsubara N, Ye Z, Keam B, Damião R, Li T, McQuarrie K, Jia B, De Porre P, Martin J, Todd MB, Fizazi K.

Lancet Oncol. 2018 Feb;19(2):194-206. doi: 10.1016/S1470-2045(17)30911-7. Epub 2018 Jan 8.

PMID:
29326030
13.

Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.

Barocas DA, Alvarez J, Resnick MJ, Koyama T, Hoffman KE, Tyson MD, Conwill R, McCollum D, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hashibe M, Kaplan SH, Paddock LE, Stroup AM, Wu XC, Penson DF.

JAMA. 2017 Mar 21;317(11):1126-1140. doi: 10.1001/jama.2017.1704. Erratum in: JAMA. 2017 May 23;317(20):2134.

14.

Quality-of-life outcomes in men treated for localized prostate cancer.

Litwin MS, Hays RD, Fink A, Ganz PA, Leake B, Leach GE, Brook RH.

JAMA. 1995 Jan 11;273(2):129-35.

PMID:
7799493
15.

Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial.

Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ.

Lancet Oncol. 2018 Oct;19(10):1404-1416. doi: 10.1016/S1470-2045(18)30456-X. Epub 2018 Sep 10.

PMID:
30213449
16.

Quality of life three years after diagnosis of localised prostate cancer: population based cohort study.

Smith DP, King MT, Egger S, Berry MP, Stricker PD, Cozzi P, Ward J, O'Connell DL, Armstrong BK.

BMJ. 2009 Nov 27;339:b4817. doi: 10.1136/bmj.b4817.

17.

Quality of life profile of general Vietnamese population using EQ-5D-5L.

Nguyen LH, Tran BX, Hoang Le QN, Tran TT, Latkin CA.

Health Qual Life Outcomes. 2017 Oct 11;15(1):199. doi: 10.1186/s12955-017-0771-0.

18.

Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.

19.

Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (Prostate Cancer Treatment, your experience) study.

Drummond FJ, Kinnear H, O'Leary E, Donnelly, Gavin A, Sharp L.

J Cancer Surviv. 2015 Jun;9(2):361-72. doi: 10.1007/s11764-014-0419-6. Epub 2015 Jan 7.

PMID:
25563819
20.

Psychosocial interventions for men with prostate cancer.

Parahoo K, McDonough S, McCaughan E, Noyes J, Semple C, Halstead EJ, Neuberger MM, Dahm P.

Cochrane Database Syst Rev. 2013 Dec 24;(12):CD008529. doi: 10.1002/14651858.CD008529.pub3. Review.

PMID:
24368598

Supplemental Content

Support Center